Increased cavernosal relaxation by Phoneutria nigriventer toxin, PnTx2-6, via activation at NO/cGMP signaling

International Journal of Impotence Research

Volumn 24, Issue 2, 2012, Pages 69-76

  Nunes, K P ^a,b   Wynne, B M ^b   Cordeiro, M N ^c   Borges, M H ^c   Richardson, M ^c   Leite, R ^d   Delima, M E ^a   Webb, R C ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c Ezequiel Dias Foundation   (Brazil)

^d FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

cGMP; erectile dysfunction; NO; Phoneutria nigriventer; PnTx2 6 toxin

Indexed keywords

CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; NEURONAL NITRIC OXIDE SYNTHASE; OMEGA CONOTOXIN GVIA; PHENYLEPHRINE; SPIDER VENOM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROSTIMULATION; MALE; MOUSE; NONHUMAN; PENIS; PENIS ERECTION; PHONEUTRIA NIGRIVENTER; PRIAPISM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPIDER;

ANIMALS; CYCLIC GMP; DIABETES MELLITUS, EXPERIMENTAL; DRUG EVALUATION, PRECLINICAL; ERECTILE DYSFUNCTION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE III; OMEGA-CONOTOXIN GVIA; PENIS; PEPTIDES; SIGNAL TRANSDUCTION; SPIDER VENOMS;

EID: 84858698931     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2011.47     Document Type: Article

References (40)

1. Nunes KP. Animal toxins as potential pharmacologycal tools for treatment of erectile dysfunction. In: De Lima ME (ed). In: Animal toxins: State of the art Perspectives in health and biotechnology. UFMG Editora: Belo Horizonte, 2009, pp 314-322.
2. Bucaretchi F, Deus Reinaldo CR, Hyslop S, Madureira PR, De Capitani EM, Vieira RJ. A clinico-epidemiological study of bites by spiders of the genus Phoneutria. Rev Inst Med Trop Sao Paulo 2000; 42: 17-21.
3. Bucaretchi F, Mello SM, Vieira RJ, Mamoni RL, Blotta MH, Antunes E et al. Systemic envenomation caused by the wandering spider Phoneutria nigriventer, with quantification of circulating venom. Clin Toxicol (Phila) 2008; 46: 885-889.
4. Mattiello-Sverzut AC, Fontana MD, Diniz CR, da Cruz-Hofling MA. Pathological changes induced by PhTx1 from Phoneutria nigriventer spider venom in mouse skeletal muscle in vitro. Toxicon 1998; 36: 1349-1361. (Pubitemid 28352727)
5. Mattiello-Sverzuta AC, da Cruz-Hofling MA. Toxin 2 (PhTx2), a neurotoxic fraction from Phoneutria nigriventer spider venom, causes acute morphological changes in mouse skeletal muscle. Toxicon 2000; 38: 793-812. (Pubitemid 30047000)
6. Borges MH, de Lima ME, Stankiewicz M, Pelhate M, Cordeiro MN, Beirao PSL. Structural and functional diversity in the venom of spiders of the genus Phoneutria. In: de Lima ME, Pimenta AMC, Martin-Eauclaire MF, Zingali R, Rochat H (eds). Animal Toxins: State of the Art Perspectives in Health and Biotechnology. Editora UFMG: Belo Horizonte, 2009, pp 291-309.
7. Nunes KP, Costa-Goncalves A, Lanza LF, Cortes SF, Cordeiro MN, Richardson M et al. Tx2-6 toxin of the Phoneutria nigriventer spider potentiates rat erectile function. Toxicon 2008; 51: 1197-1206.
8. Andrade E, Villanova F, Borra P, Leite K, Troncone L, Cortez I et al. Penile erection induced in vivo by a purified toxin from the Brazilian spider Phoneutria nigriventer. BJU Int 2008; 102: 835-837.
9. Villanova FE, Andrade E, Leal E, Andrade PM, Borra RC, Troncone LR et al. Erection induced by Tx2-6 toxin of Phoneutria nigriventer spider: Expression profile of genes in the nitric oxide pathway of penile tissue of mice. Toxicon 2009; 54: 793-801.
10. Nunes KP, Cardoso FL, Cardoso Jr. HC, Pimenta AMC, De Lima ME. Animal toxins as a potential pharmacological tools for the tratment of erectile dysfunction. In: de Lima ME, Pimenta AMC, Martin-Eauclaire MF, Zingali R, Rochat H (eds). Animal Toxins: State of the Art Perspectives in Health and Biotechnology. Editora UFMG: Belo Horizonte, 2009, pp 313-322.
11. Diniz MR, Theakston RD, Crampton JM, Nascimento Cordeiro M, Pimenta AM, De Lima ME et al. Functional expression and purification of recombinant Tx1, a sodium channel blocker neurotoxin from the venom of the Brazilian 00armed00 spider, Phoneutria nigriventer. Protein Expr Purif 2006; 50: 18-24. (Pubitemid 44648750)
12. Martin-Moutot N, Mansuelle P, Alcaraz G, Dos Santos RG, Cordeiro MN, De Lima ME et al. Phoneutria nigriventer toxin 1: A novel, state-dependent inhibitor of neuronal sodium channels that interacts with micro conotoxin binding sites. Mol Pharmacol 2006; 69: 1931-1937. (Pubitemid 43894310)
13. 2+ oscillation frequency in GH3 cells. J Neurochem 1999; 72: 1472-1481. (Pubitemid 29140818)
14. Araujo DA, Cordeiro MN, Diniz CR, Beirao PS. Effects of a toxic fraction PhTx2 from the spider Phoneutria nigriventer on the sodium current. Naunyn Schmiedebergs Arch Pharmacol 1993; 347: 205-208. (Pubitemid 23068174)
15. Matavel A, Fleury C, Oliveira LC, Molina F, de Lima ME, Cruz JS et al. Structure and activity analysis of two spider toxins that alter sodium channel inactivation kinetics. Biochemistry 2009; 48: 3078-3088.
16. Matavel A, Cruz JS, Penaforte CL, Araujo DA, Kalapothakis E, Prado VF et al. Electrophysiological characterization and molecular identification of the Phoneutria nigriventer peptide toxin PnTx2-6. FEBS Lett 2002; 523: 219-223. (Pubitemid 34786088)
17. Nunes KP, Cordeiro MN, Richardson M, Borges MN, Dini SOF, Cardoso VN et al. NO-induced vasorelaxation in response to PnTx2-6 toxin from Phoneutria nigriventer spider in rat cavernosal tissue. J Sex Med 2010; 12: 3879-3888.
18. Burnett AL. Nitric oxide regulation of penile erection: Biology and therapeutic implications. J Androl 2002; 23: S20-S26. (Pubitemid 34977533)
19. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am 2005; 32: 379-395, v. (Pubitemid 41607527)
20. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH. Nitric oxide: A physiologic mediator of penile erection. Science 1992; 257: 401-403.
21. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
22. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376. (Pubitemid 11169009)
23. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526. (Pubitemid 17085822)
24. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990; 170: 843-850. (Pubitemid 20249496)
25. Burnett AL. The role of nitric oxide in erectile dysfunction: Implications for medical therapy. J Clin Hypertens (Greenwich) 2006; 8(Suppl 4): 53-62.
26. Toda N, Ayajiki K, Okamura T. Nitric oxide and penile erectile function. Pharmacol Ther 2005; 106: 233-266. (Pubitemid 40603867)
27. Leite R, Giachini FR, Carneiro FS, Nunes KP, Tostes RC, Webb RC. Targets for the treatment of erectile dysfunction: Is NO/cGMP still the answer? Recent Pat Cardiovasc Drug Discov 2007; 2: 119-132. (Pubitemid 46952443)
28. Priviero FB, Leite R, Webb RC, Teixeira CE. Neurophysiological basis of penile erection. Acta Pharmacol Sin 2007; 28: 751-755. (Pubitemid 46817446)
29. Vlachopoulos C, Ioakeimidis N, Terentes-Printzios D, Stefanadis C. The triad: Erectile dysfunction-endothelial dysfunction- cardiovascular disease. Curr Pharm Des 2008; 14: 3700-3714.
30. Carneiro FS, Webb RC, Tostes RC. Emerging role for TNFalpha in erectile dysfunction. J Sex Med 2010; 7: 3823-3834.
31. Muller A, Mulhall JP. Cardiovascular disease, metabolic syndrome and erectile dysfunction. Curr Opin Urol 2006; 16: 435-443. (Pubitemid 44624578)
32. Wespes E, Schulman CC. Erectile dysfunction and cardiovascular diseases. Arch Esp Urol 2010; 63: 649-654.
33. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Construction of a surrogate variable for impotence in the Massachusetts Male Aging Study. J Clin Epidemiol 1994; 47: 457-467. (Pubitemid 24171210)
34. Moore CR, Wang R. Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl 2006; 8: 675-684. (Pubitemid 44869615)
35. Hidalgo-Tamola J, Chitaley K. Review type 2 diabetes mellitus and erectile dysfunction. J Sex Med 2009; 6: 916-926.
36. Torres FS, Silva CN, Lanza LF, Santos AV, Pimenta AM, De Lima ME et al. Functional expression of a recombinant toxin - rPnTx2-6 - active in erectile function in rat. Toxicon 2010; 56: 1172-1180.
37. Cordeiro MN. The purification and amino acid sequences of four Tx2 neurotoxins from the venom of the Brazilian 'armed' spider Phoneutria nigriventer (keys). FEBS Lett 1995; 32: 153-156.
38. Burnett AL, Chang AG, Crone JK, Huang PL, Sezen SE. Noncholinergic penile erection in mice lacking the gene for endothelial nitric oxide synthase. J Androl 2002; 23: 92-97.
39. Gonzalez-Cadavid NF, Burnett AL, Magee TR, Zeller CB, Vernet D, Smith N et al. Expression of penile neuronal nitric oxide synthase variants in the rat and mouse penile nerves. Biol Reprod 2000; 63: 704-714. (Pubitemid 30659263)
40. 2+]i in rat cortical synaptosomes. Cell Mol Biol (Noisy-le-grand) 2010; 56(Suppl): OL1223-OL1230.